Cite
Zhou D, Ren K, Wang J, et al. Erythropoietin-producing hepatocellular A6 overexpression is a novel biomarker of poor prognosis in patients with breast cancer. Oncol Lett. 2018;15(4):5257-5263doi: 10.3892/ol.2018.7919.
Zhou, D., Ren, K., Wang, J., Ren, H., Yang, W., Wang, W., Li, Q., Liu, X., & Tang, F. (2018). Erythropoietin-producing hepatocellular A6 overexpression is a novel biomarker of poor prognosis in patients with breast cancer. Oncology letters, 15(4), 5257-5263. https://doi.org/10.3892/ol.2018.7919
Zhou, Danmei, et al. "Erythropoietin-producing hepatocellular A6 overexpression is a novel biomarker of poor prognosis in patients with breast cancer." Oncology letters vol. 15,4 (2018): 5257-5263. doi: https://doi.org/10.3892/ol.2018.7919
Zhou D, Ren K, Wang J, Ren H, Yang W, Wang W, Li Q, Liu X, Tang F. Erythropoietin-producing hepatocellular A6 overexpression is a novel biomarker of poor prognosis in patients with breast cancer. Oncol Lett. 2018 Apr;15(4):5257-5263. doi: 10.3892/ol.2018.7919. Epub 2018 Feb 01. PMID: 29552165; PMCID: PMC5840743.
Copy
Download .nbib